Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan

A multicenter prospective Phase II trial

Jason Chia Hsun Hsieh, Cheng Lung Hsu, Shu Hang Ng, Cheng Hsu Wang, Kuan Der Lee, Chang Hsien Lu, Yi Fang Chang, Ruey Kuen Hsieh, Kun Huei Yeh, Chi Huang Hsiao, Sheng Yu Chen, Cheng Ying Shiau, Hung Ming Wang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. Methods: Gemcitabine 1250 mg/m2 on Days 1 and 8 and cisplatin 75 mg/m2 on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. Results: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycleswas 6.63 ± 0.40. The regimenwaswell-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. Conclusions: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.

Original languageEnglish
Article numberhyv083
Pages (from-to)819-827
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number9
DOIs
Publication statusPublished - Sep 1 2015
Externally publishedYes

Fingerprint

gemcitabine
Taiwan
Cisplatin
Disease-Free Survival
Aspiration Pneumonia
Leukopenia
Sepsis
Safety
Drug Therapy
Survival
Therapeutics
Nasopharyngeal carcinoma

Keywords

  • Chemo-phase I-II-III
  • Clinical trials
  • H & N-Med
  • Head and neck
  • Palliative care
  • Supportive care

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan : A multicenter prospective Phase II trial. / Hsieh, Jason Chia Hsun; Hsu, Cheng Lung; Ng, Shu Hang; Wang, Cheng Hsu; Lee, Kuan Der; Lu, Chang Hsien; Chang, Yi Fang; Hsieh, Ruey Kuen; Yeh, Kun Huei; Hsiao, Chi Huang; Chen, Sheng Yu; Shiau, Cheng Ying; Wang, Hung Ming.

In: Japanese Journal of Clinical Oncology, Vol. 45, No. 9, hyv083, 01.09.2015, p. 819-827.

Research output: Contribution to journalArticle

Hsieh, JCH, Hsu, CL, Ng, SH, Wang, CH, Lee, KD, Lu, CH, Chang, YF, Hsieh, RK, Yeh, KH, Hsiao, CH, Chen, SY, Shiau, CY & Wang, HM 2015, 'Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial', Japanese Journal of Clinical Oncology, vol. 45, no. 9, hyv083, pp. 819-827. https://doi.org/10.1093/jjco/hyv083
Hsieh, Jason Chia Hsun ; Hsu, Cheng Lung ; Ng, Shu Hang ; Wang, Cheng Hsu ; Lee, Kuan Der ; Lu, Chang Hsien ; Chang, Yi Fang ; Hsieh, Ruey Kuen ; Yeh, Kun Huei ; Hsiao, Chi Huang ; Chen, Sheng Yu ; Shiau, Cheng Ying ; Wang, Hung Ming. / Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan : A multicenter prospective Phase II trial. In: Japanese Journal of Clinical Oncology. 2015 ; Vol. 45, No. 9. pp. 819-827.
@article{c20ca91499234676a41dc252530efe8f,
title = "Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial",
abstract = "Objective: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. Methods: Gemcitabine 1250 mg/m2 on Days 1 and 8 and cisplatin 75 mg/m2 on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. Results: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9{\%} (complete remission rate, 9.6{\%}) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6{\%}). The mean number of cycleswas 6.63 ± 0.40. The regimenwaswell-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. Conclusions: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.",
keywords = "Chemo-phase I-II-III, Clinical trials, H & N-Med, Head and neck, Palliative care, Supportive care",
author = "Hsieh, {Jason Chia Hsun} and Hsu, {Cheng Lung} and Ng, {Shu Hang} and Wang, {Cheng Hsu} and Lee, {Kuan Der} and Lu, {Chang Hsien} and Chang, {Yi Fang} and Hsieh, {Ruey Kuen} and Yeh, {Kun Huei} and Hsiao, {Chi Huang} and Chen, {Sheng Yu} and Shiau, {Cheng Ying} and Wang, {Hung Ming}",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/jjco/hyv083",
language = "English",
volume = "45",
pages = "819--827",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan

T2 - A multicenter prospective Phase II trial

AU - Hsieh, Jason Chia Hsun

AU - Hsu, Cheng Lung

AU - Ng, Shu Hang

AU - Wang, Cheng Hsu

AU - Lee, Kuan Der

AU - Lu, Chang Hsien

AU - Chang, Yi Fang

AU - Hsieh, Ruey Kuen

AU - Yeh, Kun Huei

AU - Hsiao, Chi Huang

AU - Chen, Sheng Yu

AU - Shiau, Cheng Ying

AU - Wang, Hung Ming

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. Methods: Gemcitabine 1250 mg/m2 on Days 1 and 8 and cisplatin 75 mg/m2 on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. Results: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycleswas 6.63 ± 0.40. The regimenwaswell-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. Conclusions: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.

AB - Objective: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. Methods: Gemcitabine 1250 mg/m2 on Days 1 and 8 and cisplatin 75 mg/m2 on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. Results: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycleswas 6.63 ± 0.40. The regimenwaswell-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. Conclusions: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.

KW - Chemo-phase I-II-III

KW - Clinical trials

KW - H & N-Med

KW - Head and neck

KW - Palliative care

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=84942310951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942310951&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv083

DO - 10.1093/jjco/hyv083

M3 - Article

VL - 45

SP - 819

EP - 827

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

M1 - hyv083

ER -